You are here: Home / About Us / Associated Partners

Associated Partners

 Private Organizations:

 Agilent Technologies, Ltd (UK) 

Dr. Michael L. Gyngell is a MRI Applications Manager at Agilent Technology. He is a physicist with long experience in all aspects of MRI engineering including preclinical applications and MRI pulse sequence programming.

General description :

Agilent is the world’s premier measurement company. Agilent is a vendor of preclinical MRI systems, components, accessories and applications. They also offer relevant software solutions.          

Bio-Rad Laboratories  SA (FR)

Angel Burgaleta and Enrique Orozco  are  specialists in the market of Life Sciences Support & Sales for more than 20 years, big experience helping customer to choose techniques, develop methods and consultancy on Life Science.

General description:
"Bio-Rad Laboratories (NYSE: BIO and BIOb) continues to play a leading role in the advancement of scientific discovery by offering a broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 7,300 employees and serves more than 100,000 research and industry customers worldwide through the company's global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more.

Life Science Research:
Bio-Rad's Life Science Group develops, manufactures, and markets a wide range of laboratory instruments, apparatus, and consumables used for research in functional genomics, proteomics, and food safety. The group ranks among the top five life science companies worldwide, and maintains a solid reputation for quality, innovation, and a longstanding focus on the success of its customers. Bio-Rad's life science products are based on technologies used to separate, purify, identify, analyze, and amplify biological materials such as proteins, nucleic acids, and bacteria. These technologies include electrophoresis, imaging, multiplex immunoassay, chromatography, microbiology, bioinformatics, protein function analysis, transfection, amplification, real-time and droplet digital PCR. Bio-Rad products support researchers in laboratories throughout the world.

Roles and main tasks:
They will give our support to the project, training in specific techniques, well in situ at CNIC or in our training facilities in Spain. Most important aspects of this would cover:

  • PCR Techniques
  • Concepts and applications on Real Time PCRMIQE      guidelinest
  • Optimizing QRTPCR, factors that can influence      their efficiency
  •  Concept and applications for Digital PCR
  • Chromatography Techniques
  • FPLC, another vision of this approach
  • Protein electrophoresis and      blotting
  • Imaging analysis 1D
  •  Differential expresion analysis in 2D gels
  • Cuantitative Western Blotting.  
  •  Validation methods
CROmed Research & Service Centers Ltd (HU)   

General description:

CROmed Research and Service Centers Ltd is a private company dedicated to in vivo small and large animal studies.Their animal models and experiences helps the researchers to develop new therapies mainly in Central Nervous System, Oncology and Cardiology. In vivo imaging models and extended collaboration network with academia and researchers serves to get quick and reliable answers for the most important preclinical questions before clinical study investments.
Exiqon A/S (DK)

Peter Mouritzen

Dr. Peter Mouritzen, Vice President Research and Development at Exiqon which include both Diagnostics, Services, and Life Science. He joined Exiqon in 2000 and has been responsible for the development of a variety of Life Science molecular tools for LNA™ based detection of nucleic acids and bringing these tools to the market. During this period, Exiqon has developed tools and detection technologies to support the entire workflow in miRNA research from sample preparation, over miRNA profiling with arrays and qPCR, including validation by qPCR and in situ hybridization, to functional analysis with LNA™ miRNA inhibitors. For mRNA qPCR, Exiqon developed the Universal Probe Library, which today is sold by Roche Applied Sciences.

General description:

Exiqon is a public Danish biotech company (SME) with a staff of around 85 employees and facilities in Copenhagen (DK) and Boston (MA). The company has two Divisions: 1) Life Sciences, which focus on development of molecular tools for RNA research - in particular microRNA and lncRNA - using the Exiqon proprietary locked nucleic acid (LNA™) technology. The tools allow sensitive and specific analysis of miRNAs as well as functional analysis of different RNA species by using LNA™ based antisense oligo nucleotides.  2) Diagnostics, which identifies miRNA biomarkers and develop diagnostic tests. The division conducts Exiqons own cancer diagnostics programs with the aim of identifying biomarkers in different cancer types as well as to develop diagnostic assays. Exiqon also have Services department which acts as a core for internal project including biomarker discovery and validation. Services also provides services for-fee where miRNA expression analyses and profiling is conducted for researchers in both pharma and academia on microarray, qPCR and NGS platforms. Other genomic NGA analyses are also available.

Roles and main tasks:

The role of Exiqon within this consortium is to conduct training by participating in workshops and by presenting.

Imegen_logo Instituto de Medicina Genómica (ES)   


Javier Garcia Planells


Dr. Javier Garcia Planells (Scientific Director) Ph.D. degree in Biological Sciences. President of the Spanish Association of Prenatal Diagnosis. Founder of the Instituto de Genética Médica y Molecular, one of the first companies dedicated to genetic diagnosis in Spain, and Genagen S.L. He holds the accreditation in Human Genetics granted by the Spanish Society of Human Genetics (registration number 123). In 2004 he received the significant Reina Sofia Prize for his professional career in the field of hereditary neurological diseases. Member of the Board of the Spanish Association of Human Genetics (AEGH). He actively participates in the development of different good practice guides for the study of genetic diseases in organisms such as the aforementioned AEGH, European Molecular Genetics Quality Network and Organization for Economic Co-operation and Development.

General description:

Instituto de Medicina Genómica  is a biomedical company whose mission is to improve human health and quality of life of people by providing services of high quality genetic testing on the diagnosis, prognosis, therapy and prevention. By making use of our extensive experience in the fields of genetics, genomics and R&D, and according to high standards of quality, we provide our services to Hospitals, Clinics, Laboratories and Companies. To achieve that, we use the most advanced genomic technologies, supplying services of high accuracy in very short turnaround times. We offer a complement to the research capabilities of companies, industries, hospitals, universities and research centres. We can manage the entire research project or just a part, including planning, fundraising, development and technical implementation.

Roles and main tasks:

Instituto de Medicina Genomica (IMEGEN), as Associated Partner, will actively participate in the complementary training/research related to CardioNext by undertaking the following tasks:

  • To host PhD students providing access to all the infrastructure available in the company and supervision of research work
  • To participate in organization of courses/workshops for CardioNext students
  • To participate in co-mentorship of PhD students involving: future career advice, introduction to entrepreneurial activities, Genetic and Genomics diagnostic and research
  • To contribute to the overall preparation of the training programme
 Masthercell (BE)

Gisèle Deblandre, Director of Project Management with MaSTherCell. Previously Director of Development with Cardio3 Biosciences where she led clinical development of C-Cure, a cell-based therapeutic product for ischemic heart disease and Director of Program Management at Laboratory of Pediatric Hepatology and Cell Therapy at the Université Catholique de Louvain.

General description:

Masthercell is a European based Contract Development and Manufacturing Organization, dedicated to Cell-Based Advanced Therapeutic Medicinal Products. GMP facility of 600 square meters for production of cells with therapeutic use, R&D labs dedicated to technology transfer and process development. A team of cell-therapy experts combining people from the academics with stem cell expertise and from the industry trained in GMPs

 Metabolon Inc  (US) 



General description:

Metabolon is a diagnostics and services company offering the industry's leading biochemical profiling platform. Their patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization

 miRagen Therapeutics (US)

miRagen’s Management Team and scientific directors have extensive experience in oligonucleotide therapeutics discovery, translational science and drug development. The research and development group at miRagen is highly capable, well published and would be an excellent site for training young scientists.

General description:

miRagen Therapeutics is a privately held biotechnology company working to develop new microRNA-targeting therapeutics for human diseases of significant unmet need. Understanding and therapeutically targeting microRNAs that contribute to the pathogenesis of cardiovascular disease is a major area of focus for the company.

Logo_novartisNovartis (UK)


Nicolau Beckmann   

Nicolau Beckmann works in the area of biomedical imaging at the Analytical Sciences and Imaging research platform from Novartis.

General description:

Novartis is a pharmaceutical company with headquarters in Basel, Switzerland. It has research sites in Boston, Basel, Shanghai, San Francisco and Singapore. 

Roles and main tasks:

The support provided by to the CardioNext project is mainly in the area of training.

Philips Healthcare Iberia (ES)

Javier Sanchez

General description:

Philips Healthcare (PH) is one of the Product Divisions (PD) of Royal Philips Electronics. In the field of Magnetic Resonance Philips Healthcare is at the edge of the technology since 1982. From this early stages Philips is in the cutting edge of the Magnetic Resonance technology providing high quality MR scanners. During this period PH has become a leader in cardiac MR with the inclusion of very advance acquisition methods to perform 3D acquisitions of the cardiac muscle in a single breath hold and providing the higher gradient strength in the market.

Philips Healthcare Iberia has experience in the development of new acquisition and quantification procedures as well as in image post-processing to obtain quantitative information of the MR data. PH is going to lead the technological aspects of MR imaging for better characterization of the infarct and the follow up of the regeneration treatment.  Philips Healthcare has been involved in other European Projects related with cardiac disease such as EUHeart or CareMI.

SilicoLife  SilicoLife (PT)


Simão Soares 

Simão Soares is CEO at SilicoLife, he holds a MSc in Bioinformatics from the University of Minho and was visiting researcher at the Center for Microbial Biotechnology, Technical University of Denmark, in the integration of omics data with genome scale models to reveal diabetes type 2 biomarkers. He collaborated with the CCTC and CEB-IBB research centers from University of Minho in the fields of Bioinformatics and Systems Biology, with published work in computational biology top ranked journals.

General description:

SilicoLife is a computational biology company with a strong experience in the integration of new high-throughput experimental omics data with genome scale models and in the use of network-based methods to reveal network hotspots, key physiologically relevant molecules or sub-networks linked to a specific condition or state, which can be used as disease biomarkers or possible drug targets.

SilicoLife also builds computational models of microbial cells and develops proprietary state-of-the-art algorithms to find the most efficient pathways between raw-material and end-product, streamlining the strain design process and exploring non-intuitive pathway modifications.

It benefits from the expertise and international recognition of its founding team in the fields of Bioinformatics and Systems Biology with several published works in mathematical and computational methods for modeling, simulation and optimization of microbial strains.

Roles and main tasks:

SilicoLife will contribute with their experience in the integration of omics data with genome scale models and in the use of it to reveal hotspots. SilicoLife will also contribute with solutions for the visualization of biological data.

Thermo_logo Thermo Fisher Scientific Inc. (ES)

Natividad García


Gemma Roldán

Javier Rodríguez

Natividad García (Development Manager), 15 years working in Thermo Fisher Scientific as Software Development Manager leading LIMS development for Biotech and Clinical markets. 5 years working in GSK as R&D Information Resources Manger leading the automation of a High Throughput Screening research site in Madrid. Astronomer on  duty  and  research  with  Chemistry Models  of  Interstellar Clouds  in  IRAM (http://www.iram‐

Gemma Roldán (Maintenance Contract Co-ordinator Spain, Portugal & Benelux Informatics), 14 years working in Thermo Fisher Scientific for Informatics holding several positions: LIMS Consultant, Validation Project Manager and currently as Contract Maintenance Coordinator, member of the Spanish Community Action Council for corporate social action and leading the CSR Wakeup! project.

Javier Rodriguez  (Sales Rep) 20 years  working  in  Thermo  Fisher  Scientific  as  Sales  Representative  for  the  CMD ‐Chromatography & Mass División.

General description:

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With the acquisition of Life Technologies, we are now a $17 billion company, with almost 50,000 employees around the world  and  serve  customers  within  pharmaceutical and  biotech  companies,  hospitals  and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries.

We create value for our key stakeholders through four premier brands, Life Technologies, Thermo Scientific, Fisher Scientific and the new Unity Lab Services brand, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management.

Our scale and depth give us deep applications expertise, and we use that expertise to help our customers solve complex challenges whether they are in life sciences, healthcare, environmental or industrial markets.

Roles and main tasks:  

As the world leader in serving science, Thermo Fisher Scientific has both an interest in, and a responsibility for inspiring students to pursue careers in science, technology, engineering and math. Thus we support a wide range of activities which inspire a passion for science at all ages and stimulate people to take up the professions of researcher. CardioNext, “Next generation training in cardiovascular research and innovation” proposal coordinated by CNIC” is an innovative PhD focused on cardiovascular translational research. Thermo Fisher Scientific S.L., as Associated Partner, will actively participate in the complementary training/research training related to CardioNext that will be organized by the consortium, and will contribute to the overall preparation of a coherent training programme for the network.

Uniqure uniQure (NL)


Bas Blits

Bas Blits, PhD: The work of Bas focusses on the development of proof of concept for gene therapy. Bas Blits holds a PhD in Neuroscience. He defended his thesis entitled: “Cell and gene therapy: Experimental strategies for spinal cord regeneration” in 2001 at the free University Amsterdam. After this, he went to The Miami Project to Cure Paralysis where he co-founded the Miami Project viral vector core and worked on regenerative therapies following spinal cord injury in the rodent. For his work for the viral vector core he supported many projects in many animal models. Furthermore, he was an associate member of the Christopher Reeve Paralysis Research Consortium. In 2005 he returned to the laboratory of Joost Verhaagen before he joined Amsterdam Molecular Therapeutics, nowadays uniQure, as a senior scientist. At uniQure he is driving several preclinical programs, such as gene therapy for Duchenne muscular dystrophy, Parkinson’s, acute intermittent porfyria and Hemophilia. He is heading the neurobiology group as well as the in vivo group.

General description:

uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world’s first stable and scalable AAV manufacturing platform. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD. uniQure’s Glybera is the first approved gene therapy in the Western world.

Roles and main tasks:

Contribution of the training network will be comprising training of two students. The training will mostly include sharing our knowledge and experience with bringing a gene therapy product from bench to bedside to market. Production and characterization of the viral vector will be a part of this training using our dedicated procedures. Furthermore, the trainee will be introduced into the four research areas that are currently ongoing in uniQure, namely neurobiology/in vivo, immunology, emerging technologies, and vector development. This should provide a wide overview of key activities within the company.



WitecWITec Wissenschaftliche Instrumente und Technologie GmbH (DE)          


Elena Bailo

Dr. Elena Bailo (Area Manager España & Portugal)  is Area Manager España&Portugal at WITec GmbH in Barcelona, Spain with a background in chemistry.

General Decription:

WITec is a manufacturer of high-resolution optical and scanning probe microscopy solutions for scientific and industrial applications:

  • Scanning Near-field optical Microscopy (SNOM or NSOM)
  • Atomic Force Microscopy (AFM)
  • Confocal Microscopy
  • Raman Microscopy (Ultrasensitive and fast Raman Imaging)

Focusing on innovations and constantly introducing new technologies, we are the leading experts for your optical, structural and chemical imaging tasks.

Roles and main tasks:

WITec collaborates with this project supporting the students in his research with Confocal Raman Imaging.

Non-Profit Organizations
EMBO Molecular Medicine (UK)
EMBO organization enables the best science by supporting talented researchers stimulating scientific excahnge and advancing policies for a world-class european research environment. EMBO is an organization of 1500 leading life scientist members that fosters new generations of researchers to produce world-class scientific results. EMBO helps young scientists to advance their research, promote their international reputations adn ensure their mobility. Courses, workshops, conferences and scientific journals, like EMBO Molecular Medicine, disseminate the latest research and offer training in cutting-edge techniques to maintain high standards of excellence in research practice. EMBO helps to shape science and research policy by seeking input and feedback from our community and by following closely the trends in science in Europe.
Généthon (FR)

 Fulvio Mavilio

Fulvio Mavilio, Ph.D., is Scientific Director of Genethon (Evry, France), and Professor of Molecular Biology and University of Modena and Reggio Emilia (Modena, Italy). He was Director of  Discovery of  Molmed S.p.A. (2002-2005) and  founder and  Chief Scientific Officer of Genera S.p.A. (1999-2002), two biotechnology companies in Milan. He had previously served as co-Director of the San Raffaele-Telethon Institute of Gene Therapy in Milan (1995 to 2002), as director of the Molecular Hematology unit of the San Raffaele Institute (1989 to 1995), as Visiting Scientist at the Wistar Institute, Philadelphia, (1986 to1988), as group leader in the Department of Hematology-Oncology of an the Istituto Superiore di Sanità, a government authority in Rome (1984 to 1988), and as staff scientist of the Institute of Experimental Medicine of the Italian National Research Council in Rome (1982 to1984). Prof. Mavilio is member of the European Molecular Biology Association (EMBO), member of the Therapies Scientific Committe of the International Rare Disease Research Consortium (IRDiRC), Chairman of the Educational Committee of the American Society of Gene Therapy (ASGT), and member of the Editorial Board of many international journals in the fields of genetics, molecular biology and gene therapy. He graduated in Biology at the University of Rome in 1976, and obtained a Ph.D. in Medical Genetics at the School of Medicine of the same University in 1979. He was awarded a Special Fellowship by the Italian National  Research  Council,  Rome (1978-1982), and   a   U.S.  Public  Health  Service International Research Fellowship by the Fogarty International Center, NIH, Bethesda (1986-1988). Prof. Mavilio is an expert and a pioneer in the fields of gene therapy and stem cell research, and author of over 140 articles in major international journals. He was born in Naples in 1953.

General description:

Généthon is the largest European non-profit institution dedicated to gene therapy of genetic diseases. It was founded in 1995 and is located in Evry, France. Funded by the Association Française contre les Myopathies (AFM), Généthon has >200 employees and a budget (2012) of >28 M€. Its activities range from basic research in vector design and in the biology and immunology of vector-host response to the development and manufacturing of clinical-grade vector under GMP standards. Généthon is part of the AFM’s Institute of Biotherapy, which iincludes I-Stem in Evry, the Institute of Myology at the Hospital Pitié-Salpétrière in Paris, and the Atlantic Gene Therapies Institute in Nantes.

SIBSIB Swiss Institute of Bioinformatics (CH)    


Ioannis Xenarios


email | web | web Swiss-Prot

General description:

The  Swiss Institute of Bioinformatics  (SIB) is an academic, non-profit foundation recognised of public utility and established in 1998. SIB coordinates research and education in bioinformatics throughout Switzerland and provides high quality bioinformatics services to the national and international research community.

The Vital-IT group maintains resources in bioinformatics and computational biology and support projects ranging from human to non-human research. The Swiss-Prot group maintain knowledge-base resources used by the scientific community. Both of these groups helps research and clinical groups in Switzerland and beyond.

 Public Organizations:

Cardiovascular Research Center at Mount Sinai School of Medicin (US) 

Roger J. Hajjar,

General description:

The Cardiovascular Research Center is home to scientists, physician-scientists, medical/graduate, and undergraduate students focused on basic and translational cardiovascular research. Investigators from various disciplines, including biomedical engineering, development biology, vascular biology, and pharmacogenomics, join their talents here to pursue cross-disciplinary goals using fundamental discoveries to prevent and reverse heart failure and atherosclerosis.  

ImpreialImperial College London (UK)  

General description:

Imperial College was ranked fifth in the world in the 2007 Times Higher Education Supplement world university rankings. Imperial employs 3,000 academic and research staff and educates almost 12,000 students. The Faculty of Engineering is one of three Faculties within Imperial College. The Faculty comprises 9 Departments, and is one of the largest engineering faculties in the UK.

Johns Hopkins University (US)

General descrption:

The mission of The Johns Hopkins University is to educate its students and cultivate their capacity for life-long learning, to foster independent and original research, and to bring the benefits of discovery to the world. After more than 130 years, Johns Hopkins remains a world leader in both teaching and research. Eminent professors mentor top students in the arts and music, the humanities, the social and natural sciences, engineering, international studies, education, business and the health professions. Those same faculty members, and their research colleagues at the university's Applied Physics Laboratory, have each year since 1979 won Johns Hopkins more federal research and development funding than any other university.

London Research Institute-Cancer Research (UK)


 Dr. Holger Gerhardt


Holger Gerhardt studied Biology in Darmstadt and Neurobiology in Tuebingen, Germany, where he also completed his PhD in Cell Biology in 2000. During his post-doctoral research with Christer Betsholtz at Gothenburg University, Sweden, Dr. Gerhardt conceptualized the endothelial tip and stalk cells; a discovery that kick-started his work on endothelial guidance and vascular patterning. Since 2004, he is a group leader at the London Research Institute-Cancer Research UK. Dr. Gerhardt is EMBO Young Investigator (2007) and recipient of the prestigious Lister Prize (2008). In 2009, he received the Walter Fleming Medal of the German Society for Cell Biology, in 2011 the Judah Folkman Award of the North American Vascular Biology organization and in 2012, the Hooke Medal of the British Society of Cell Biology. Since 2010, Dr. Gerhardt also heads the Vascular Patterning Laboratory at the VIB, KU Leuven, Belgium, building an integrated research team across the two institutions to combine expertise in vascular disease models with his cell biology approach to unravel principles of vascular network formation in development and disease. Dr. Gerhardt’s research activity will become part of the new Francis Crick Institute opening in central London in 2015.

General description:

The LRI is the flag ship basic science institute of Cancer Research UK with 46 group leaders working in a wide spectrum of biomedical sciences. It will become part of the new Francis Crick Institute in central London in 2015. The vascular biology lab at the LRI started in 2004 and works in a joint venture with the vascular patterning lab at the VIB, KU Leuven, Belgium, to unravel the basic principles and the molecular control of vascular patterning in development and diseases.

 Swiss Federal Institute of Technology  Zurich (CH)


Sebastian Kozerke

Sebastian Kozerke, PhD, is a Professor of Bioimaging at the Institute for Biomedical Engineering of the University and ETH Zurich, Switzerland, where he leads the Cardiovascular Magnetic Resonance research. He is also Professor and Chair of CMR Physics at King’s College London, UK.Prof. Kozerke is the author of more than 145 peer-reviewed journal articles and 5 patents. 

General description:

The Swiss Federal Institute of Technology Zurich ranks among the top universities in the world with popular rankings placing ETHZ as the best university in Swizerland and on the main European continent. Twenty-one Nobel Laureates are associated with ETH Zurich. The Institute for Biomedical Engineering has bee the first joint institute of the University adn ETH Zurich and was founded in 1971 as one of the pioneering institutions in Europe fully dedicated to Biomedical Engineering adn Medical Imaging sciences. The IBT is structures into five divisions, which cover a wide range of activities in collaboration with clinincal and biological partner institutions.

Roles and main tasks:

The partner offers training in Magnetic Resonance pulse sequence programming for fast imaging and the design and implementation of complex algorithms for data processing, reconstruction and quantification of cardiac imaging.


 Swiss Institute for Experimental Cancer Research (CH)

Dr. Michele De Palma


Michele De Palma Assistant Professor,obtained his Ph.D. in 2004 from the University of Turin Medical School and performed post-doctoral training at the San Raffaele Institute in Milan, Italy. In 2012 he was appointed Assistant Professor at The Swiss Institute for Experimental Cancer Research (ISREC), Swiss Federal Institute of Technology Lausanne (EPFL), Switzerland ( He is a recipient of a European Research Council Starting grant. The De Palma’s laboratory investigates the interplay between macrophages and tumor angiogenesis, with a focus on how these stromal components of the tumor regulate tumor responses to anticancer therapies. The De Palma’s lab also explores new gene transfer strategies that exploit monocytes/macrophages as cellular vehicles for the delivery of biotherapeutics to tumors and regenerating tissues.

General description:

EPFL is one of the two leading federal Swiss universities (together with ETH, Zurich) and is ranked 32th among the World’s top universities. EPFL comprises 7 Schools, of which one is the School of Life Sciences. The School of Life Sciences currently hosts more than 50 research groups structured in 4 Institutes: Bioengineering; Neurosciences; Global Health; and the Swiss Institute for Experimental Cancer Research (ISREC). Currently, ISREC hosts 20 research groups and more than two hundred collaborators boasting a large critical mass of researchers. Genetically engineered mouse models of human cancer are increasingly being employed at ISREC to elucidate the roles of signaling pathways and regulatory mechanisms in tumors, as well as the complex interplay of cancer cells with normal cells in their "tumor microenvironment". Key research topics at ISREC include: mechanisms of cancer development and pre-clinical testing of mechanism-targeted drugs; angiogenesis and lymphangiogenesis; inflammation; cancer stem cells; cell signaling in development and cancer; structural biology. The different research groups at ISREC maintain close ties with many scientific institutions and universities in the Lausanne area and abroad. Moreover, the recent integration of ISREC in the School of Life Sciences at EPFL has fostered interactions between cancer biologists and bioengineers (with expertise in biomolecular engineering, cellular engineering, micro- and nanotechnologies, materials, modeling and computation).

Roles and main tasks:

The De Palma’s lab will contribute expertise to study the interactions between monocytes/macrophages and angiogenesis in the heart. By employing lentiviral vector-based gene transfer, monocytes/macrophages will be engineered to modify their expression of genes (including microRNAs) that have a role in heart remodeling and repair.

University of Oxford (UK)

Profesor Robin Choudhury qualified in medicine at the University of Oxford with postgraduate training in London (Royal Brompton, Hammersmith et al) and New York (Cardiovascular Institute of the Mount Sinai Medical Center). He is a Wellcome Trust Senior Research Fellow in Clinical Science and Professor of Cardiovascular Medicine at the University of Oxford; Consultant Cardiologist at the John Radcliffe Hospital and Clinical Director of the Oxford Acute Vascular Imaging Centre.  His research interests focus on the development and application of imaging techniques (especially molecular imaging) for the characterization of atherosclerosis, thrombosis and vascular inflammation and on interventions that regress atherosclerosis. His laboratory is supported by the Wellcome Trust, the British Heart Foundation and the National Institute for Health Research, Oxford Comprehensive Biomedical Research Centre. He is a Fellow of the European Society of Cardiology and of the Royal College of Physicians.

General description:

The Oxford Acute Vascular Imaging Centre ( at the John Radcliffe Hospital is an internationally unique facility dedicated to clinical research in acute coronary syndromes (heart attack and unstable angina) and stroke and TIA. There is a 3T MRI scanner functionally joined to an interventional angiography suite by a mechanised rapid transfer system.

AVIC is a unit within the Investigative Medicine Division (IMD) which is part of the Radcliffe Department of Medicine, University of Oxford. 

CEUUniversity San Pablo-CEU (ES)

Dr. Coral Barbas

Coral Barbas  Based at Universidad CEU San Pablo (USP-CEU), Madrid, Spain, Coral Barbas is Ph. D. in Chemical Sciences (1987). Marie Curie fellow (2005/2006). Vice-rector for Research since 2011 and Professor in Analytical Chemistry (since 2007). Coral is the Founder and Director of the Center for Metabolomics and Bionalysis (CEMBIO)   (ruego subáis el link al CEMBIO)

Principal Researcher for all the studies developed within the CEMBIO. The research made at the CEMBIO is related to search of diagnostic and prognostic markers of different diseases such as several cardiovascular, parasitic (schistosomiasis, leishmaniasis) and pulmonary diseases, or cancer, as well as to unveil mechanisms related to drug action, toxicity and resistance. Moreover, the group develops analytical methodologies suited for Bioanalysis and quality control of pharmaceuticals. Since 1996 and as a result of this research activity, more than 150 scientific papers have been published in journals included in JCR. Coral has longstanding collaborations in Latin American Countries.

General description: 

The Fundación Universitaria San Pablo CEU (FUSP-CEU) is a private non-lucrative institution devoted to Research and Education, with over 80 years of experience within the educational Spanish spectrum, and 24 educational and research centers in Spain. Among the FUSP-CEU universities, CEU San Pablo University (USP-CEU) is considered and consolidated as one of the best private Spanish universities. Although FUSP-CEU has been providing Education for eight decades, it is in 1993 when the USP-CEU was officially recognised as the first Private University in Spain.

This means that CEU San Pablo University poses the educational experience accumulated along years and the needed motivation to continue developing our Research throughout Horizon 2020. Research has been always considered the Core of our general project and a priority within the USP-CEU. This is the reason why the Center for Metabolomics and Bioanalysis (CEMBIO) based within the Faculty of Pharmacy has been present in the Regional, National and European Research Programmes and Calls Spectrum since 1993.

Forschungszentrum Borstel -- Leibniz- Zentrum fr Medizin und Biowissenschaften (DE)

Dr. Dominik Schwudke

Forschungszentrum Borstel


Dr. Dominik Schwudke is the head of the Division of Bianalytical Chemistry at the Research Center Borstel (Germany). His group focuses on the identification and quantitation of membrane components and immunological active biomolecules. He is specialized in the analysis of lipids, glyco-conjugates, and cell wall components. The group has made very relevant advances in the field of lipidomics and they have gained a great experience in the development and applications of OMICs workflows and methods for structural characterization. His group has also played a pioneering role in the implementation of unique competences in mass spectrometry (MS) and nuclear magnetic resonance (NMR) approaches enabling in-depth studies of metabolic processes in biological model system as well as clinical samples. He has also made important contributions with relevant biological results.

General Information

The Research Center Borstel was founded in 1947 as a research institute with the main focus on tuberculosis and leprosy. 1963, Borstel is constituted as a foundation, the term "Research Institute Borstel, Institute for Experimental Biology and Medicine" was changed into "Research Center Borstel - Center for Medicine and Biosciences" in 1995.The Federal Government and the local state of Schleswig-Holstein already realized the importance of this center many years ago and took up the RCB into the so-called "Blue List", later renamed Leibniz Association. This is a German-wide association of 89 non-university research institutions that combine excellence with relevance in their respective research missions. In order to demonstrate its closeness to this scientific umbrella organization, the centre was renamed "Research Center Borstel - Leibniz-Center for Medicine and Biosciences" in the year 2004.









  • © 2013 by CardioNext